<DOC>
	<DOCNO>NCT00028860</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery treat patient urinary tract cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Following Surgery Treating Patients With Urinary Tract Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine time treatment failure disease-free survival patient high-risk transitional cell carcinoma urothelium treat adjuvant paclitaxel , ifosfamide , carboplatin , gemcitabine . - Determine tolerability feasibility regimen patient . OUTLINE : Patients stratify accord disease stage . Patients receive paclitaxel IV 3 hour follow carboplatin IV 1 hour day 1 , ifosfamide IV 1 hour day 1-3 , filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 4 continue blood count recover . Treatment repeat every 21 day total 2 course . Beginning 3 week completion second course chemotherapy , patient receive gemcitabine IV 30 minute day 1 8 carboplatin IV 1 hour day 1 . Patients also receive G-CSF SC daily day 2-6 begin day 9 continue blood count recover . Treatment repeat every 21 day total 2 course absence disease progression unacceptable toxicity . Patients follow 3 month , every 6 month 2 year , annually 3 year . PROJECTED ACCRUAL : A total 10-30 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis transitional cell carcinoma urothelium include bladder , ureter , renal pelvis T3b4 , N0 , M0 OR Any T , N13 , M0 Cystectomy within past 8 week PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 01 Life expectancy : At least 12 month Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine great ULN Albumin great ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy except curatively treat carcinoma situ cervix nonmelanoma skin cancer No active serious infection , serious underlie medical condition , dementia , significantly alter mental status would preclude study participation No known hypersensitivity Cremophor EL No preexist clinically significant grade 2 great neuropathy No AIDS ( HIV positivity alone allow ) No know hypersensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy malignancy No neoadjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy malignancy Surgery : See Disease Characteristics Other : No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>localize transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>